Nilotinib (Tasigna) for CML

Medical Letter on Drugs and Therapeutics

Volumn 50, Issue 1283, 2008, Pages 26-27

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; GLYCOPROTEIN P INHIBITOR; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; 4 METHYL N (3 (4 METHYLIMIDAZOL 1 YL) 5 (TRIFLUOROMETHYL)PHENYL) 3 ((4 PYRIDIN 3 YLPYRIMIDIN 2 YL)AMINO)BENZAMIDE; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; ANTINEOPLASTIC AGENT; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER REGRESSION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONSTIPATION; CROSS RESISTANCE; DRUG ABSORPTION; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG COST; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; ELECTROLYTE DISTURBANCE; FATIGUE; FLUID RETENTION; HEADACHE; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; LONG QT SYNDROME; NAUSEA; NEUTROPENIA; PHILADELPHIA CHROMOSOME POSITIVE CELL; PLEURA EFFUSION; PRURITUS; QT PROLONGATION; RASH; SHORT SURVEY; SIDE EFFECT; SUDDEN DEATH; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; ARTICLE; DRUG ANTAGONISM; DRUG INTERACTION;

ANTINEOPLASTIC AGENTS; DRUG INTERACTIONS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 42449149932     PISSN: 0025732X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (10)

1. Gleevec (STI-571) for chronic myeloid leukemia. Med Lett Drugs Ther 2001;43:49.
2. BJ Druker et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408.
3. Dastinib (Sprycel) for CML and Ph+ ALL. Med Lett Drugs Ther 2007; 49:6.
4. HM Kantarjian et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007; 110:3540.
5. P le Coutre et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 2008; 111:1834,
6. A Quintas-Cardama et al. Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood 2007; 109:497.
7. HA Bradeen et al. Comparison of imatinib mesylate, dastinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 2006; 108:2332.
8. H Kantarjian et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 2007; 109:5143.
9. CYP3A and drug interactions. Med Lett Drugs Ther 2005; 47:54.
10. Drug interactions. Med Lett Drugs Ther 2003; 45:46.